Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLK5 | Q9Y337 | 3/20 | 0.71 |
| ▸ | PSEN1 | P49768 | 3/20 | 0.56 |
| ▸ | PSEN2 | P49810 | 3/20 | 0.56 |
| ▸ | APH1B | Q8WW43 | 3/20 | 0.56 |
| ▸ | NCSTN | Q92542 | 3/20 | 0.56 |
| ▸ | APH1A | Q96BI3 | 3/20 | 0.56 |
| ▸ | PSENEN | Q9NZ42 | 3/20 | 0.56 |
| ▸ | APP | P05067 | 1/20 | 0.56 |
| ▸ | ATM | Q13315 | 1/20 | 0.55 |
| ▸ | CTSS | P25774 | 2/20 | 0.53 |
| ▸ | CTSL | P07711 | 1/20 | 0.53 |
| ▸ | CTSB | P07858 | 1/20 | 0.53 |
| ▸ | CTSK | P43235 | 1/20 | 0.53 |
| ▸ | ACE | P12821 | 1/20 | 0.51 |
| ▸ | REN | P00797 | 3/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9815894 | 1.00 | KLK5 (0.71) | KLK5PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL9832414 | 1.00 | KLK5 (0.71) | KLK5PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL6873021 | 1.00 | KLK5 (0.71) | KLK5PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL9482833 | 0.90 | KLK5 (0.72) | KLK5PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL9833378 | 0.90 | KLK5 (0.72) | KLK5PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL2155955 | 0.90 | KLK5 (0.61) | KLK5PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL7392856 | 0.89 | KLK5 (0.67) | KLK5PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL8538004 | 0.88 | KLK5 (0.66) | KLK5PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL12751287 | 0.88 | KLK5 (0.66) | KLK5PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL8539590 | 0.88 | KLK5 (0.66) | KLK5PSEN1PSEN2APH1BNCSTN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0260668-B1 | SEPARATION OF DIASTEREOMERS | WARNER-LAMBERT COMPANY (US) | 1991-10-09 | — | — | EP | claimed |
| US-4978759-A | REACTING MELDRUM*S ACID WITH PROTECTED AMINO ACID, CYCLIZATION DECYCLIZING, REDUCTION AND DEPROTECTING; STATINE | SANOFI, S.A. AND INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (FR) | 1990-12-18 | — | — | US | claimed |
| US-10077288-B2 | Hydroxystatin derivatives for the treatment of arthrosis | MERCK PATENT GMBH (DE) | 2018-09-18 | — | — | US | disclosed |
| EP-2877485-B1 | HYDROXYSTATIN DERIVATIVES FOR TREATMENT OF ARTHROSIS | MERCK PATENT GMBH (DE) | 2018-03-14 | — | — | EP | disclosed |
| EP-2877485-B1 | HYDROXYSTATIN DERIVATIVES FOR TREATMENT OF ARTHROSIS | MERCK PATENT GMBH (DE) | 2018-03-14 | — | — | EP | disclosed |
| US-9624264-B2 | Hydroxystatin derivatives for the treatment of arthrosis | MERCK PATENT GMBH (DE) | 2017-04-18 | — | — | US | disclosed |
| US-9624264-B2 | Hydroxystatin derivatives for the treatment of arthrosis | MERCK PATENT GMBH (DE) | 2017-04-18 | — | — | US | disclosed |
| US-9624264-B2 | Hydroxystatin derivatives for the treatment of arthrosis | MERCK PATENT GMBH (DE) | 2017-04-18 | — | — | US | disclosed |
| US-20170081361-A1 | HYDROXYSTATIN DERIVATIVES FOR THE TREATMENT OF ARTHROSIS | MERCK PATENT GMBH (DE) | 2017-03-23 | — | — | US | disclosed |
| US-20170081361-A1 | HYDROXYSTATIN DERIVATIVES FOR THE TREATMENT OF ARTHROSIS | MERCK PATENT GMBH (DE) | 2017-03-23 | — | — | US | disclosed |
| US-20170081361-A1 | HYDROXYSTATIN DERIVATIVES FOR THE TREATMENT OF ARTHROSIS | MERCK PATENT GMBH (DE) | 2017-03-23 | — | — | US | disclosed |
| US-4816598-A | 4-Amino-butanoic acid derivatives | SANOFI (FR) | 1989-03-28 | — | — | US | disclosed |
| EP-0300287-A2 | Process for the reduction of ketones | MERCK PATENT GmbH (DE) | 1989-01-25 | — | — | EP | disclosed |
| US-4749687-A | Renin inhibitors containing statine or derivatives thereof | PFIZER INC. (US) | 1988-06-07 | — | — | US | disclosed |
| EP-0260668-A2 | Separation of diastereomers | WARNER-LAMBERT COMPANY (US) | 1988-03-23 | — | — | EP | disclosed |
| US-4681972-A | Separation of diastereomers | WARNER-LAMBERT COMPANY (US) | 1987-07-21 | — | — | US | disclosed |
| EP-0155809-A2 | Renin inhibitors containing statine or derivatives thereof | PFIZER INC. (US) | 1985-09-25 | — | — | EP | disclosed |
| EP-0077029-B1 | RENIN INHIBITORY PEPTIDES | MERCK & CO. INC. (US) | 1985-08-21 | — | — | EP | disclosed |
| US-4384994-A | HYPOTENSIVE AND HYPOALDOSTERONE AGENTS | MERCK & CO., INC. (US) | 1983-05-24 | — | — | US | disclosed |
| EP-0077029-A2 | Renin inhibitory peptides | MERCK & CO. INC. (US) | 1983-04-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170081361-A1 | HYDROXYSTATIN DERIVATIVES FOR THE TREATMENT OF ARTHROSIS | CTSD, CTSB, CTSZ | KLK5 332/4885PSEN1 3776/4885PSEN2 3724/4885 |
| US-10077288-B2 | Hydroxystatin derivatives for the treatment of arthrosis | CTSD, CTSB, CTSZ | KLK5 332/4885PSEN1 3776/4885PSEN2 3724/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.